Astrazeneca PLC (AZN) Upgraded at Sanford C. Bernstein
Sanford C. Bernstein upgraded shares of Astrazeneca PLC (NYSE:AZN) from a market perform rating to an outperform rating in a research report released on Friday morning, MarketBeat reports. They currently have $39.00 price objective on the stock, up from their prior price objective of $30.00.
Other equities analysts have also issued research reports about the company. BidaskClub lowered Astrazeneca PLC from a sell rating to a strong sell rating in a research note on Friday, August 4th. Liberum Capital lowered Astrazeneca PLC from a buy rating to a hold rating in a research note on Thursday, September 14th. Investec raised Astrazeneca PLC from a hold rating to a buy rating in a research note on Wednesday, August 9th. Pareto Securities raised Astrazeneca PLC from a sell rating to a hold rating in a research note on Tuesday, August 1st. Finally, Morgan Stanley lowered Astrazeneca PLC from an overweight rating to an equal weight rating in a research note on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $34.20.
Shares of Astrazeneca PLC (NYSE AZN) opened at 34.02 on Friday. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The company has a market capitalization of $86.14 billion, a PE ratio of 22.32 and a beta of 0.74. The company’s 50 day moving average is $30.33 and its 200-day moving average is $31.81.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.46. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business’s revenue was down 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.83 earnings per share. On average, analysts expect that Astrazeneca PLC will post $1.91 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Astrazeneca PLC (AZN) Upgraded at Sanford C. Bernstein” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-upgraded-at-sanford-c-bernstein/1587984.html.
The firm also recently declared a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were issued a $0.44 dividend. The ex-dividend date was Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 44.92%.
Institutional investors have recently made changes to their positions in the business. PVG Asset Management Corp bought a new stake in shares of Astrazeneca PLC in the first quarter worth about $8,242,000. Liberty Mutual Group Asset Management Inc. bought a new stake in shares of Astrazeneca PLC in the first quarter worth about $890,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Astrazeneca PLC in the first quarter worth about $12,038,000. Blair William & Co. IL increased its holdings in shares of Astrazeneca PLC by 62.3% in the second quarter. Blair William & Co. IL now owns 42,117 shares of the company’s stock worth $1,436,000 after acquiring an additional 16,174 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of Astrazeneca PLC in the second quarter worth about $808,000. Institutional investors own 14.17% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.